









Mercado
/
Acciones
/
nasdaq-hrow
/

Harrow Inc

HROW

39.010USD

+0.220+0.57%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

1.43BCap. mercado

PérdidaP/E TTM



Harrow Inc

39.010

+0.220+0.57%

Descripción general Compañía Finanzas Análisis

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Información de la empresa

Símbolo de cotizaciónHROW

Nombre de la empresaHarrow Inc

Fecha de salida a bolsaFeb 08, 2013

Director ejecutivoMr. John P. Saharek

Número de empleados382

Tipo de seguridadOrdinary Share

Fin del año fiscalFeb 08

Dirección1A Burton Hills Blvd

CiudadNASHVILLE

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited States of America

Código postal37215

Teléfono16157334731

Sitio Webhttps://www.harrow.com/

Símbolo de cotizaciónHROW

Fecha de salida a bolsaFeb 08, 2013

Director ejecutivoMr. John P. Saharek

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.89M

+11.03%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

777.84K

+36.92%

Mr. John P. Saharek

President and Chief Executive Officer of ImprimisRx

467.39K

+58.62%

Dr. Adrienne L. Graves, Ph.D.

Independent Director

Mrs. Lauren P. Silvernail

Independent Director

Mr. Perry J. Sternberg

Lead Independent Director

Mr. Amir Shojaei, Ph.D.

Chief Scientific Officer

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.89M

+11.03%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

777.84K

+36.92%

Mr. John P. Saharek

President and Chief Executive Officer of ImprimisRx

467.39K

+58.62%

Dr. Adrienne L. Graves, Ph.D.

Independent Director

Mrs. Lauren P. Silvernail

Independent Director

Mr. Perry J. Sternberg

Lead Independent Director

Desglose de ingresos

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Product Sales Net

47.74M

0.00%

Transfer of acquired product sales/profit

86.00K

0.00%

Sin datos

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Product Sales Net

47.74M

0.00%

Transfer of acquired product sales/profit

86.00K

0.00%

Estadísticas de accionistas

Actualizado: sáb., 16 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

Opaleye Management Inc.

10.55%

Baum (Mark L)

7.80%

BlackRock Institutional Trust Company, N.A.

6.09%

Private Capital Management

5.26%

The Vanguard Group, Inc.

5.03%

Otro

65.27%

Accionistas

Proporción

Opaleye Management Inc.

10.55%

Baum (Mark L)

7.80%

BlackRock Institutional Trust Company, N.A.

6.09%

Private Capital Management

5.26%

The Vanguard Group, Inc.

5.03%

Otro

65.27%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor/Hedge Fund

18.79%

Investment Advisor

18.12%

Hedge Fund

17.30%

Individual Investor

15.72%

Research Firm

2.46%

Bank and Trust

0.35%

Pension Fund

0.29%

Sovereign Wealth Fund

0.07%

Insurance Company

0.03%

Otro

26.87%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

345

26.63M

72.57%

-2.99M

2025Q1

354

25.78M

70.87%

-4.22M

2024Q4

350

26.13M

73.38%

-4.49M

2024Q3

325

25.90M

72.95%

-2.80M

2024Q2

296

24.70M

70.19%

-6.36M

2024Q1

284

26.34M

74.95%

-7.20M

2023Q4

279

28.26M

80.94%

-4.94M

2023Q3

275

28.51M

81.73%

-152.59K

2023Q2

265

25.64M

85.30%

+312.85K

2023Q1

246

23.86M

79.81%

+1.57M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Opaleye Management Inc.

3.94M

10.72%

-4.80K

-0.12%

Jun 04, 2025

Baum (Mark L)

2.60M

7.08%

+461.94K

+21.61%

Apr 21, 2025

BlackRock Institutional Trust Company, N.A.

2.27M

6.2%

-1.07K

-0.05%

Mar 31, 2025

Private Capital Management

1.89M

5.15%

+195.64K

+11.54%

Mar 31, 2025

The Vanguard Group, Inc.

1.86M

5.07%

-6.65K

-0.36%

Mar 31, 2025

Kaufman (Daniel)

1.68M

4.59%

-222.91K

-11.69%

Aug 12, 2024

Braidwell LP

956.84K

2.61%

+49.80K

+5.49%

Mar 31, 2025

Geode Capital Management, L.L.C.

774.08K

2.11%

+52.97K

+7.35%

Mar 31, 2025

Boll (Andrew R)

777.84K

2.12%

+209.75K

+36.92%

Apr 21, 2025

State Street Global Advisors (US)

786.48K

2.14%

-41.22K

-4.98%

Mar 31, 2025

ETFs relacionados

Actualizado: mié., 6 de ago

Nombre

Proporción

SPDR S&P Pharmaceuticals ETF

1.81%

Invesco Dorsey Wright Healthcare Momentum ETF

1.59%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.12%

iShares U.S. Pharmaceuticals ETF

0.49%

First Trust Small Cap Growth AlphaDEX Fund

0.37%

Invesco Dorsey Wright SmallCap Momentum ETF

0.36%

iShares Micro-Cap ETF

0.22%

ProShares Ultra Nasdaq Biotechnology

0.12%

Invesco Nasdaq Biotechnology ETF

0.11%

Fidelity Small-Mid Multifactor ETF

0.1%

SPDR S&P Pharmaceuticals ETF

Proporción1.81%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporción1.59%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción1.12%

iShares U.S. Pharmaceuticals ETF

Proporción0.49%

First Trust Small Cap Growth AlphaDEX Fund

Proporción0.37%

Invesco Dorsey Wright SmallCap Momentum ETF

Proporción0.36%

iShares Micro-Cap ETF

Proporción0.22%

ProShares Ultra Nasdaq Biotechnology

Proporción0.12%

Invesco Nasdaq Biotechnology ETF

Proporción0.11%

Fidelity Small-Mid Multifactor ETF

Proporción0.1%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

